Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-6194 injection site study in healthy adults
NCT06649877Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2023
- Primary completion
- Jul 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PT101 in ulcerative colitis (UC), systemic lupus erythematosus (SLE), Vitiligo and 1 more (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Last at 4 weeks, Area Under the Concentration-Time Curve from Time 0 to Infinity at 4 weeks and 5 more. Started Mar 2023; status: completed.
02
Drugs
PT101
03
Conditions
ulcerative colitis (UC)systemic lupus erythematosus (SLE)Vitiligoatopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06649877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649877.